Reports Q3 revenue $174,000, consensus $3.68M. "We are pleased with our progress during the third quarter towards completion of our NDA submission for OPNT003 and preparations to support a potential launch next year. Our agreement with Emergent Biosolutions to buy out the royalty for NARCAN(R) Nasal Spray underscores our steadfast commitment to the promise of OPNT003 and provides additional and non-dilutive financial flexibility as we advance towards commercialization. We also achieved the completion of enrollment in our Phase 2 clinical trial for alcohol use disorder."
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OPNT:
- Opiant (OPNT) Stock Skyrockets on Indivior’s $145M Buyout Offer
- Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
- Indivior To Acquire Opiant Pharmaceuticals
- Indivior PLC to Acquire Opiant Pharmaceuticals
- Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022